Report on the 2021 Aniridia North America symposium on PAX6, aniridia, and beyond.
Aniridia
Aniridic keratopathy
Biennial aniridia meeting
Clinical treatment
Cornea
Dry eye
Genetics of eye development
Glaucoma
Lens
Patient advocacy
Retina
Journal
The ocular surface
ISSN: 1937-5913
Titre abrégé: Ocul Surf
Pays: United States
ID NLM: 101156063
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
14
03
2023
revised:
25
05
2023
accepted:
26
05
2023
medline:
4
9
2023
pubmed:
30
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
The inaugural Aniridia North America (ANA) Symposium was held on the first weekend in November 2021 in Charlottesville, VA, at the University of Virginia. The purpose of this meeting was to bring together an international group of scientists, physicians, patient advocacy groups, and individuals with aniridia to discuss recent advances in knowledge about aniridia and other congenital eye diseases and the development of potential treatments for congenital eye disorders using personalized medicine. Leaders in several areas of eye research and clinical treatment provided a broad perspective on new research advances that impact an understanding of the causes of the damage to the eye associated with aniridia and the development of novel treatments for this and related disorders. Here we summarize the research discussed at the symposium.
Identifiants
pubmed: 37247841
pii: S1542-0124(23)00052-6
doi: 10.1016/j.jtos.2023.05.010
pii:
doi:
Substances chimiques
PAX6 Transcription Factor
0
PAX6 protein, human
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-431Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.